@prefix this: <http://purl.org/np/RAiZJgHWMM9MvNEfMa1q3X96X_ky7IUQD7DaZkwfzuqEA> .
@prefix sub: <http://purl.org/np/RAiZJgHWMM9MvNEfMa1q3X96X_ky7IUQD7DaZkwfzuqEA#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:Head {
  this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_7551> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_7551> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01112> ;
    a rdf:Statement ;
    rdfs:label "cefuroxime axetil tablets are a cephalosporin antibacterial drug indicated for the treatment of the following infections due to susceptible bacteria 1 pharyngitis tonsillitis adults and pediatric patients 1 1 acute bacterial otitis media pediatric patients 1 2 acute bacterial maxillary sinusitis adults and pediatric patients 1 3 acute bacterial exacerbations of chronic bronchitis adults and pediatric patients 13 years and older 1 4 uncomplicated skin and skin structure infections adults and pediatric patients 13 years and older 1 5 uncomplicated urinary tract infections adults and pediatric patients 13 years and older 1 6 uncomplicated gonorrhea adults and pediatric patients 13 years and older 1 7 early lyme disease adults and pediatric patients 13 years and older 1 8 to reduce the development of drug resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients 13 years and older with mild to moderate pharyngitis tonsillitis caused by susceptible strains of streptococcus pyogenes limitations of use the efficacy of cefuroxime axetil tablets in the prevention of rheumatic fever was not established in clinical trials the efficacy of cefuroxime axetil tablets in the treatment of penicillin resistant strains of streptococcus pyogenes cefuroxime axetil tablets are indicated for the treatment of pediatric patients who can swallow tablets whole with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis streptococcus pyogenes cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients 13 years and older with mild to moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae haemophilus influenzae limitations of use the effectiveness of cefuroxime axetil tablets for sinus infections caused by b lactamase producing haemophilus influenzae moraxella catarrhalis see clinical studies 14 1 cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with mild to moderate acute bacterial exacerbations of chronic bronchitis caused by susceptible strains b lactamase negative strains or b lactamase negative strains cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with mild to moderate acute bacterial exacerbations of chronic bronchitis caused by susceptible strains of streptococcus pneumoniae haemophilus influenzae haemophilus parainfluenzae cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with uncomplicated skin and skin structure infections caused by susceptible strains of staphylococcus aureus streptococcus pyogenes cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with uncomplicated urinary tract infections caused by susceptible strains of escherichia coli klebsiella pneumoniae cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with uncomplicated gonorrhea urethral and endocervical caused by penicillinase producing and non penicillinase producing susceptible strains of neisseria gonorrhoeae neisseria gonorrhoeae cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with early lyme disease erythema migrans caused by susceptible strains of borrelia burgdorferi to reduce the development of drug resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB01112> bl:category bl:Drug .
}
sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
    npx:hasSignature "RTbG/8c5B/otxgRaMMiO+Alc/158rF7f3u/IdCFHJZPGAA5OSNKkKx2ZyTak0kXtxTMA0PR4i8M7g4lDFQMv7dJB+/UVSfUru6asNIB3Si3NKbYhjF/NkHkcSioQD7ho4ue0kxiUzGtr8FDe3mDgPQHiRu1pbUFuImP4s1867Ck=" ;
    npx:hasSignatureTarget this: .
  this: dct:created "2021-06-21T09:37:02.383+02:00"^^xsd:dateTime ;
    dct:creator orcid:0000-0002-1468-3557 ;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM> ;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM> ;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}